MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse

Background Adolescent marijuana use is associated with increased risk for schizophrenia. We previously reported that marijuana misuse in conjunction with specific cannabinoid receptor 1 (CNR1) genetic variants (rs12720071-G-allele carriers) contributed to white-matter (WM) brain volume deficits in schizophrenia patients. In this study, we assessed the influence of another cannabinoid-related gene, mitogen-activated protein kinase 14 (MAPK14), and potential MAPK14–CNR1 gene–gene interactions in conferring brain volume abnormalities among schizophrenia patients with marijuana abuse/dependence. MAPK14 encodes a member of the MAPK family involved in diverse cellular processes, including CNR1-induced apoptosis. Method We genotyped 235 schizophrenia patients on nine MAPK14 tag single nucleotide polymorphisms (tSNPs). Approximately one quarter of the sample had marijuana abuse or dependence. Differential effects of MAPK14 tSNPs on brain volumes across patients with versus without marijuana abuse/dependence were examined using ANCOVA. Results Of the MAPK14 tSNPs, only rs12199654 had significant genotype effects and genotype × marijuana misuse interaction effects on WM volumes. rs12199654-A homozygotes with marijuana abuse/dependence had significantly smaller total cerebral and lobar WM volumes. The effects of MAPK14 rs12199654 on WM volume deficits remained significant even after controlling for the CNR1 rs12720071 genotype. There were significant main effects of the MAPK14 CNR1 diplotype and diplotype × marijuana interaction on WM brain volumes, with both genetic variants having additive contributions to WM volume deficits only in patients with marijuana misuse. Conclusions Given that CNR1-induced apoptosis is preceded by increased MAPK phosphorylation, our study suggests that potential MAPK14–CNR1 gene–gene interactions may mediate brain morphometric features in schizophrenia patients with heavy marijuana use.

[1]  D. Gillies,et al.  Cannabis and schizophrenia. , 2014, The Cochrane database of systematic reviews.

[2]  P. Thompson,et al.  Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults. , 2012, The international journal of neuropsychopharmacology.

[3]  E. Bora,et al.  The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. , 2012, Schizophrenia bulletin.

[4]  S. Tapert,et al.  Gender effects on amygdala morphometry in adolescent marijuana users , 2011, Behavioural Brain Research.

[5]  Brian Avants,et al.  Medial temporal structures and memory functions in adolescents with heavy cannabis use. , 2011, Journal of psychiatric research.

[6]  Piotr Bogorodzki,et al.  Altered prefrontal and insular cortical thickness in adolescent marijuana users , 2011, Behavioural Brain Research.

[7]  T. Wassink,et al.  Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia , 2011, Schizophrenia Research.

[8]  T. George,et al.  The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis , 2011, Schizophrenia Research.

[9]  P. Matthews,et al.  Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS) , 2011, Schizophrenia Research.

[10]  M. Yücel,et al.  Cerebellar white-matter changes in cannabis users with and without schizophrenia , 2011, Psychological Medicine.

[11]  Ronald Pierson,et al.  Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. , 2011, Archives of general psychiatry.

[12]  M. Pérez-García,et al.  What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance? , 2011, Neuroscience & Biobehavioral Reviews.

[13]  J. Vázquez-Barquero,et al.  Cannabis use and cognitive functioning in first-episode schizophrenia patients , 2010, Schizophrenia Research.

[14]  R. Kahn,et al.  Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia , 2010, European Neuropsychopharmacology.

[15]  A. Cuadrado,et al.  Mechanisms and functions of p38 MAPK signalling. , 2010, The Biochemical journal.

[16]  M. Yücel,et al.  Structural MRI Findings in Long-Term Cannabis Users: What Do We Know? , 2010, Substance use & misuse.

[17]  Kerang Zhang,et al.  MicroRNAs and target site screening reveals a pre-microRNA-30e variant associated with schizophrenia , 2010, Schizophrenia Research.

[18]  S. Tapert,et al.  Abnormal cerebellar morphometry in abstinent adolescent marijuana users , 2010, Psychiatry Research: Neuroimaging.

[19]  P. Johnston,et al.  CEREBELLAR GREY MATTER DEFICITS, CANNABIS USE AND FIRST-EPISODE SCHIZOPHRENIA IN ADOLESCENTS AND YOUNG ADULTS , 2010, Schizophrenia Research.

[20]  J. Vázquez-Barquero,et al.  Gyrification brain abnormalities associated with adolescence and early-adulthood cannabis use , 2010, Brain Research.

[21]  L. Hunyady,et al.  Signal transduction of the CB1 cannabinoid receptor. , 2010, Journal of molecular endocrinology.

[22]  D. Linszen,et al.  Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia , 2010, Psychiatry Research: Neuroimaging.

[23]  Peter B. Jones,et al.  If cannabis caused schizophrenia--how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. , 2009, Addiction.

[24]  S. Tapert,et al.  IMAGING STUDY: Prefrontal cortex morphometry in abstinent adolescent marijuana users: subtle gender effects , 2009, Addiction biology.

[25]  J. Feldon,et al.  A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. , 2009, Schizophrenia bulletin.

[26]  Katherine B. Morton,et al.  Results from the 2008 National Survey on Drug Use and Health: National findings , 2009 .

[27]  P. McGuire,et al.  Neuroimaging in cannabis use: a systematic review of the literature , 2009, Psychological Medicine.

[28]  Mohini Ranganathan,et al.  Cannabis and psychosis/schizophrenia: human studies , 2009, European Archives of Psychiatry and Clinical Neuroscience.

[29]  M. Koch,et al.  Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment , 2009, Brain Research.

[30]  S. Kumra,et al.  Diffusion abnormalities in adolescents and young adults with a history of heavy cannabis use. , 2009, Journal of psychiatric research.

[31]  G. D. den Heeten,et al.  Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for structural hyperconnectivity? , 2009, Psychopharmacology bulletin.

[32]  P. Falkai,et al.  Comorbid substance abuse and brain morphology in recent-onset psychosis , 2009, European Archives of Psychiatry and Clinical Neuroscience.

[33]  Wiepke Cahn,et al.  Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. , 2008, The American journal of psychiatry.

[34]  L. DeLisi.  The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? , 2008, Current opinion in psychiatry.

[35]  J. van os,et al.  Letter to the Editor: The coherence of the evidence linking cannabis with psychosis , 2008, Psychological Medicine.

[36]  Vaibhav A. Diwadkar,et al.  Cannabis use and brain structural alterations in first episode schizophrenia — A region of interest, voxel based morphometric study , 2008, Schizophrenia Research.

[37]  T. Hansen,et al.  The estrogen hypothesis of Schizophrenia implicates glucose metabolism: Association study in three independent samples , 2008, BMC Medical Genetics.

[38]  G. Almazan,et al.  p38 Mitogen-Activated Protein Kinase Regulates Myelination , 2008, Journal of Molecular Neuroscience.

[39]  G. Almazan,et al.  p38 mitogen‐activated protein kinase is required for central nervous system myelination , 2007, Glia.

[40]  Robin M. Murray,et al.  Cannabis, the mind and society: the hash realities , 2007, Nature Reviews Neuroscience.

[41]  A. Arévalo-Martı́n,et al.  Cannabinoids modulate Olig2 and polysialylated neural cell adhesion molecule expression in the subventricular zone of post‐natal rats through cannabinoid receptor 1 and cannabinoid receptor 2 , 2007, The European journal of neuroscience.

[42]  A. Cuenda,et al.  p38 MAP-kinases pathway regulation, function and role in human diseases. , 2007, Biochimica et biophysica acta.

[43]  P. Schlattmann,et al.  Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[44]  Barbara Napolitano,et al.  Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia , 2007, British Journal of Psychiatry.

[45]  P. Crespo,et al.  Mxi2 promotes stimulus‐independent ERK nuclear translocation , 2007, The EMBO journal.

[46]  M. Koch,et al.  The effect of chronic peripubertal cannabinoid treatment on deficient object recognition memory in rats after neonatal mPFC lesion , 2007, European Neuropsychopharmacology.

[47]  S. Kumra.  Schizophrenia and cannabis use. , 2007, Minnesota medicine.

[48]  J. Quickfall,et al.  Brain neuroimaging in cannabis use: a review. , 2006, The Journal of neuropsychiatry and clinical neurosciences.

[49]  L. Jarskog,et al.  Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations , 2006, Current opinion in psychiatry.

[50]  I. McGregor,et al.  Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats , 2006, Journal of psychopharmacology.

[51]  J. Os,et al.  Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people , 2004, BMJ : British Medical Journal.

[52]  F. Benes.  Strategies for improving sensitivity of gene expression profiling: regulation of apoptosis in the limbic lobe of schizophrenics and bipolars. , 2006, Progress in brain research.

[53]  P. Fried,et al.  Neurocognitive consequences of marihuana--a comparison with pre-drug performance. , 2005, Neurotoxicology and teratology.

[54]  T. Powles,et al.  Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. , 2005, Blood.

[55]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[56]  I. McGregor,et al.  Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats , 2004, Journal of psychopharmacology.

[57]  H. Osada,et al.  Exip, a splicing variant of p38α, participates in interleukin‐1 receptor proximal complex and downregulates NF‐κB pathway , 2004 .

[58]  J. Os,et al.  Early adolescent cannabis exposure and positive and negative dimensions of psychosis. , 2004, Addiction.

[59]  N. Andreasen,et al.  Validity of symptom assessment in psychotic disorders: information variance across different sources of history , 2004, Schizophrenia Research.

[60]  Marquis P Vawter,et al.  Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree , 2004, Schizophrenia Research.

[61]  H. Osada,et al.  Exip, a splicing variant of p38alpha, participates in interleukin-1 receptor proximal complex and downregulates NF-kappaB pathway. , 2004, FEBS letters.

[62]  Michael Koch,et al.  Chronic Pubertal, but not Adult Chronic Cannabinoid Treatment Impairs Sensorimotor Gating, Recognition Memory, and the Performance in a Progressive Ratio Task in Adult Rats , 2003, Neuropsychopharmacology.

[63]  V. Campbell,et al.  Tetrahydrocannabinol‐induced neurotoxicity depends on CB1 receptor‐mediated c‐Jun N‐terminal kinase activation in cultured cortical neurons , 2003, British journal of pharmacology.

[64]  W. Hall,et al.  Testing hypotheses about the relationship between cannabis use and psychosis. , 2003, Drug and alcohol dependence.

[65]  Glyn Lewis,et al.  Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study , 2002, BMJ : British Medical Journal.

[66]  J. Borrell,et al.  Cannabinoids Promote Oligodendrocyte Progenitor Survival: Involvement of Cannabinoid Receptors and Phosphatidylinositol-3 Kinase/Akt Signaling , 2002, The Journal of Neuroscience.

[67]  R. de Graaf,et al.  Cannabis use and psychosis: a longitudinal population-based study. , 2002, American journal of epidemiology.

[68]  J. Gfroerer,et al.  Initiation of Marijuana Use: Trends, Patterns and Implications , 2002 .

[69]  Greg Harris,et al.  Structural MR image processing using the BRAINS2 toolbox. , 2002, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[70]  R. Nicoll,et al.  Endocannabinoid Signaling in the Brain , 2002, Science.

[71]  M. Webster,et al.  Application of cDNA microarrays to examine gene expression differences in schizophrenia , 2001, Brain Research Bulletin.

[72]  J. Girault,et al.  Cannabinoids activate p38 mitogen‐activated protein kinases through CB1 receptors in hippocampus , 2001, Journal of neurochemistry.

[73]  J. Avruch,et al.  Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. , 2001, Physiological reviews.

[74]  V. Pickel,et al.  Ultrastructural Localization of the CB1 Cannabinoid Receptor in μ-Opioid Receptor Patches of the Rat Caudate Putamen Nucleus , 2001, The Journal of Neuroscience.

[75]  T. Wenger,et al.  Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study☆ , 2000, Peptides.

[76]  A. Howlett,et al.  Cellular signal transduction by anandamide and 2-arachidonoylglycerol. , 2000, Chemistry and physics of lipids.

[77]  J. K. Lee,et al.  Constitutive activity and differential localization of p38α and p38β MAPKs in adult mouse brain , 2000, Journal of neuroscience research.

[78]  L. Johnston,et al.  Marijuana and Youth , 2000 .

[79]  K. Mielke,et al.  JNK and p38 stresskinases — degenerative effectors of signal-transduction-cascades in the nervous system , 2000, Progress in Neurobiology.

[80]  Y. Benjamini,et al.  On the Adaptive Control of the False Discovery Rate in Multiple Testing With Independent Statistics , 2000 .

[81]  N. Andreasen,et al.  COMPREHENSIVE ASSESSMENT OF SYMPTOMS AND HISTORY (CASH) , 2000 .

[82]  N C Andreasen,et al.  Improving tissue classification in MRI: a three-dimensional multispectral discriminant analysis method with automated training class selection. , 1999, Journal of computer assisted tomography.

[83]  D. Storm,et al.  Hippocampal Neurotoxicity of Δ9-Tetrahydrocannabinol , 1998, The Journal of Neuroscience.

[84]  N C Andreasen,et al.  Automatic atlas-based volume estimation of human brain regions from MR images. , 1996, Journal of computer assisted tomography.

[85]  J. Ehrhardt,et al.  Regional brain abnormalities in schizophrenia measured with magnetic resonance imaging. , 1994, JAMA.

[86]  N C Andreasen,et al.  Voxel processing techniques for the antemortem study of neuroanatomy and neuropathology using magnetic resonance imaging. , 1993, The Journal of neuropsychiatry and clinical neurosciences.

[87]  N C Andreasen,et al.  The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. , 1992, Archives of general psychiatry.

[88]  J. Mazziotta,et al.  Rapid Automated Algorithm for Aligning and Reslicing PET Images , 1992, Journal of computer assisted tomography.

[89]  J. Nurnberger,et al.  A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. , 1991, Nucleic acids research.

[90]  J. Talairach,et al.  Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging , 1988 .

[91]  R. Murray,et al.  Is schizophrenia a neurodevelopmental disorder? , 1987, British medical journal.

[92]  Sven Andréasson,et al.  CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts , 1987, The Lancet.

[93]  D. Weinberger.  Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.